Agenus (NASDAQ:AGEN) issued its earnings results on Thursday. The biotechnology company reported ($0.40) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.28) by ($0.12), MarketWatch Earnings reports.
NASDAQ:AGEN traded down $0.01 during trading hours on Thursday, hitting $2.95. 1,071,161 shares of the stock traded hands, compared to its average volume of 1,550,627. Agenus has a fifty-two week low of $1.54 and a fifty-two week high of $6.02. The company has a market cap of $336.00 million, a P/E ratio of -2.40 and a beta of 2.09.
A number of brokerages have commented on AGEN. Zacks Investment Research upgraded Agenus from a “sell” rating to a “hold” rating in a research note on Thursday, January 24th. ValuEngine downgraded Agenus from a “buy” rating to a “hold” rating in a research note on Thursday, January 31st. Finally, BidaskClub downgraded Agenus from a “buy” rating to a “hold” rating in a research note on Friday, January 25th.
COPYRIGHT VIOLATION NOTICE: “Agenus (AGEN) Posts Quarterly Earnings Results, Misses Expectations By $0.12 EPS” was reported by WKRB News and is the property of of WKRB News. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.wkrb13.com/2019/03/14/agenus-agen-posts-quarterly-earnings-results-misses-expectations-by-0-12-eps.html.
Agenus Company Profile
Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.
Read More: What is a Fiduciary?
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.